Pharmaceuticals

Fundiin partners with Pharmacity to launch BNPL at a thousand drugstores in Vietnam

Fundiin and Pharmacity have forged the first-ever Buy Now Pay Later (BNPL) partnership in the pharmacy retail sector, with Fundiin being the most popular BNPL provider inVietnam and Pharmacity emerging as the regional leading drugstore chain. HO CHI MINH CITY, Vietnam, Nov. 13, 2023 /PRNewswire/...

2023-11-13 14:58 2640

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB), and abst...

2023-11-13 08:10 2469

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center inSouth Korea. Colorectal cancer (CRC) is o...

2023-11-13 08:00 2886

Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability

Company attributes B+ rating to progress related to its Human Rights Management Declaration, eco-friendly shipping box and the establishment of an internal ESG Committee SEOUL, South Korea, Nov. 10, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total so...

2023-11-10 20:00 3911

Shaping Global Policy: IFPA's Psoriatic Disease Response Index in the Western Pacific

STOCKHOLM, Nov. 10, 2023 /PRNewswire/ -- Psoriatic disease, recognized as a serious noncommunicable disease by the World Health Organization (WHO), impacts millions worldwide. A pioneering advocacy tool, the Psoriatic Disease Response Index, has emerged to facilitate a vital policy discussion, dr...

2023-11-10 19:18 3961

H2U Secures Strategic Investment from InnoTherapy as Recognition from Seoul Clinical Laboratories (SCL)

H2U platform enters the South Korean healthcare sector, driving AI-powered data analytics to expand their digital health offerings TAIPEI, Nov. 10, 2023 /PRNewswire/ -- H2U, Taiwan's premier digital health brand, proudly announced another successful round of funding this year after receiving rec...

2023-11-10 17:48 2799

MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results

SHENZHEN, China, Nov. 9, 2023 /PRNewswire/ -- On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, inthe United States. This milestone was marked by...

2023-11-10 08:00 1905

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

* Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment.  * The starting dose (0.7mg) of PMC-403 showed potential in improving eyesight for neovascular age-related macular degeneration patients with suboptimal response to cur...

2023-11-09 21:00 1542

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to$1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in al...

2023-11-09 15:05 1395

Noah Launches "Play The Full Game" Campaign with Singaporean Football Legend Fandi Ahmad as Brand Ambassador

SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- Noah, the telehealth platform tailored for men and created by Ordinary Folk, is pleased to announce the launch of its "Play The Full Game" campaign and the appointment ofFandi Ahmad as Noah's brand ambassador. The campaign aims to empower men to have the co...

2023-11-09 14:31 2248

West Pharmaceutical Services Appoints Nilesh Shah as Vice President and General Manager of Emerging Markets

SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, today announced it has appointed Nilesh Shah to serve as Vice President and General Manager of Emerging Mark...

2023-11-09 12:58 9523

DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells

Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function...

2023-11-09 08:15 2073

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...

2023-11-09 08:10 4746

Telix to Present at Jefferies London Healthcare Conference 2023

MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023. The presentation will take place o...

2023-11-09 04:51 1843

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology

TAIPEI, Nov. 8, 2023 /PRNewswire/ --  * AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients. * Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Acc...

2023-11-08 23:23 1973

Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development

SUZHOU, China, Nov. 8, 2023 /PRNewswire/ -- On November 8, 2023, Porton Advanced announced the establishment of a strategic partnership with BioMap. BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly effi...

2023-11-08 22:31 2276

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...

2023-11-08 13:00 1796

Docquity Expands Digitized Patient Access Programs To Enhance Healthcare Outcomes in Thailand

* After a successful pilot in the Philippines, five DocquityCare Patient Access Programs (PAPs)have been launched in Thailand * DocquityCare PAP will support more than 100 hospitals and 250 healthcare professionals (HCPs) to improve patient care for those with cancer and other life-threatenin...

2023-11-08 10:00 2434

WuXi Biologics Receives AAA MSCI ESG Rating

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...

2023-11-08 08:30 1617

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...

2023-11-08 08:30 1979
1 ... 77787980818283 ... 320

Week's Top Stories